Woodline Partners LP Has $14.39 Million Holdings in Humacyte, Inc. (NASDAQ:HUMA)

Woodline Partners LP lifted its holdings in Humacyte, Inc. (NASDAQ:HUMA) by 235.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,848,802 shares of the company’s stock after purchasing an additional 2,000,268 shares during the period. Woodline Partners LP owned 2.26% of Humacyte worth $14,386,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of HUMA. CenterBook Partners LP acquired a new stake in shares of Humacyte in the 4th quarter valued at $6,463,000. Brevan Howard Capital Management LP lifted its stake in shares of Humacyte by 2,795.1% in the 4th quarter. Brevan Howard Capital Management LP now owns 876,340 shares of the company’s stock valued at $4,426,000 after purchasing an additional 846,070 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Humacyte by 10.8% in the 4th quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock valued at $28,294,000 after purchasing an additional 543,995 shares during the last quarter. Franklin Resources Inc. acquired a new stake in shares of Humacyte in the 4th quarter valued at $2,189,000. Finally, Bank of America Corp DE lifted its stake in shares of Humacyte by 160.2% in the 4th quarter. Bank of America Corp DE now owns 597,319 shares of the company’s stock valued at $3,016,000 after purchasing an additional 367,720 shares during the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Price Performance

Humacyte stock opened at $2.34 on Thursday. The firm has a market cap of $362.98 million, a price-to-earnings ratio of -1.75 and a beta of 1.64. Humacyte, Inc. has a fifty-two week low of $1.15 and a fifty-two week high of $9.97. The firm has a fifty day moving average price of $1.79 and a two-hundred day moving average price of $3.43.

Humacyte (NASDAQ:HUMA) last released its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.09. The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.46 million. As a group, sell-side analysts expect that Humacyte, Inc. will post -1.27 earnings per share for the current year.

Insider Activity at Humacyte

In other news, Director Kathleen Sebelius acquired 50,000 shares of Humacyte stock in a transaction on Tuesday, April 8th. The stock was bought at an average price of $1.32 per share, for a total transaction of $66,000.00. Following the transaction, the director now owns 91,207 shares of the company’s stock, valued at $120,393.24. The trade was a 121.34% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Dale A. Sander acquired 20,000 shares of Humacyte stock in a transaction on Thursday, April 10th. The stock was purchased at an average price of $1.53 per share, with a total value of $30,600.00. Following the transaction, the chief financial officer now directly owns 40,600 shares in the company, valued at approximately $62,118. This trade represents a 97.09% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 83,993 shares of company stock worth $118,224. Company insiders own 5.10% of the company’s stock.

Analyst Ratings Changes

HUMA has been the subject of several analyst reports. Benchmark reduced their price objective on shares of Humacyte from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, May 14th. D. Boral Capital reissued a “buy” rating and set a $25.00 target price on shares of Humacyte in a research report on Tuesday, May 13th. Finally, HC Wainwright began coverage on shares of Humacyte in a research report on Wednesday, May 14th. They set a “buy” rating and a $4.00 target price for the company. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $11.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.